GlassScriptPhysician profile
Mary F Hans
NPI 1457604878
$2,853.65
in general payments reported to CMS, 2019-2025
23 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $939 · 2022: $446 · 2023: $705 · 2024: $628 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.92 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.09 | 2021-2025 | |
| Astellas Pharma US INC | $325.88 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $307.19 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $257.73 | 2021-2024 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $186.04 | 2021-2024 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $171.13 | 2021-2024 | Slynd |
| Sumitomo Pharma America, INC. | $155.67 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $138.73 | 2021-2022 | |
| Pfizer INC. | $110.56 | 2021-2024 | |
| Therapeuticsmd, INC. | $89.67 | 2021-2022 | |
| Organon LLC | $87.90 | 2023-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $87.35 | 2021-2023 | |
| Daiichi Sankyo INC. | $76.88 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.96 | 2021-2023 | |
| Mission Pharmacal Company | $62.32 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $61.51 | 2021-2023 | Balcoltra |
| Agile Therapeutics, INC. | $40.46 | 2024 | Twirla |
| Lupin INC. | $34.65 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.73 | 2023-2024 | Xifaxan |
| Scynexis, INC. | $27.51 | 2021-2022 | |
| Provepharm INC. | $18.33 | 2025 | Bludigo |
| Virtus Pharmaceuticals LLC | $17.92 | 2021 | |
| Exact Sciences Corporation | $16.44 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.